AR113803A1 - Compuesto de pirimidina como inhibidor de jak quinasas - Google Patents

Compuesto de pirimidina como inhibidor de jak quinasas

Info

Publication number
AR113803A1
AR113803A1 ARP180103131A ARP180103131A AR113803A1 AR 113803 A1 AR113803 A1 AR 113803A1 AR P180103131 A ARP180103131 A AR P180103131A AR P180103131 A ARP180103131 A AR P180103131A AR 113803 A1 AR113803 A1 AR 113803A1
Authority
AR
Argentina
Prior art keywords
compound
inhibitor
jak kinases
pyrimidine compound
formula
Prior art date
Application number
ARP180103131A
Other languages
English (en)
Spanish (es)
Inventor
Jerry Nzerem
Marta Dabros
Robert Murray Mkinnell
Gary E L Brandt
Ryan Hudson
Jennifer Kozak
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of AR113803A1 publication Critical patent/AR113803A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)
ARP180103131A 2017-10-27 2018-10-26 Compuesto de pirimidina como inhibidor de jak quinasas AR113803A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27

Publications (1)

Publication Number Publication Date
AR113803A1 true AR113803A1 (es) 2020-06-10

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103131A AR113803A1 (es) 2017-10-27 2018-10-26 Compuesto de pirimidina como inhibidor de jak quinasas

Country Status (38)

Country Link
US (7) US10308646B2 (enExample)
EP (1) EP3672965B1 (enExample)
JP (1) JP7218364B2 (enExample)
KR (1) KR102613503B1 (enExample)
CN (1) CN111247142B (enExample)
AR (1) AR113803A1 (enExample)
AU (1) AU2018354370B2 (enExample)
BR (1) BR112020008015A2 (enExample)
CA (1) CA3074034A1 (enExample)
CL (1) CL2020001090A1 (enExample)
CR (1) CR20200180A (enExample)
CU (1) CU24671B1 (enExample)
DK (1) DK3672965T3 (enExample)
DO (1) DOP2020000083A (enExample)
EA (1) EA202091016A1 (enExample)
EC (1) ECSP20023795A (enExample)
ES (1) ES2932526T3 (enExample)
GE (2) GEP20227344B (enExample)
HR (1) HRP20221221T1 (enExample)
HU (1) HUE060401T2 (enExample)
IL (1) IL274037B2 (enExample)
LT (1) LT3672965T (enExample)
MA (1) MA49956B1 (enExample)
MD (1) MD3672965T2 (enExample)
MX (1) MX2020004255A (enExample)
NI (1) NI202000032A (enExample)
PE (1) PE20201495A1 (enExample)
PH (1) PH12020500528A1 (enExample)
PL (1) PL3672965T3 (enExample)
PT (1) PT3672965T (enExample)
RS (1) RS63608B1 (enExample)
SG (1) SG11202001706RA (enExample)
SI (1) SI3672965T1 (enExample)
SM (1) SMT202200409T1 (enExample)
TW (1) TWI789446B (enExample)
UA (1) UA125130C2 (enExample)
WO (1) WO2019084383A1 (enExample)
ZA (1) ZA202001641B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202200409T1 (it) 2017-10-27 2022-11-18 Theravance Biopharma R&D Ip Llc Composto di pirimidina come inibitore di chinasi jak
CA3121408A1 (en) * 2018-11-30 2020-06-04 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
TW202106681A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
WO2020219639A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as jak kinase inhibitors
MX2023001259A (es) * 2020-07-28 2023-05-15 Arcutis Biotherapeutics Inc Formulaciones tópicas que contienen inhibidor de jak y laureth-4.
MX2023002378A (es) * 2020-08-26 2023-05-22 Nalo Therapeutics Moduladores de proteinas de la familia de protooncogenes myc.
WO2022076771A1 (en) * 2020-10-08 2022-04-14 Icahn School Of Medicine At Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療fxr誘發之搔癢之il-31調節劑
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス, インコーポレイテッド Tyk2分解剤およびそれらの使用
JP2024544404A (ja) 2021-12-15 2024-11-29 アーキュティス・バイオセラピューティクス・インコーポレーテッド Shr0302の安定な製剤
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
DE60128709T2 (de) 2000-09-15 2007-12-27 Vertex Pharmaceuticals Inc., Cambridge Triazol-verbindungen als protein-kinase-inhibitoren
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526468A (en) 2000-12-21 2004-03-26 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
DE602006021776D1 (de) 2005-11-16 2011-06-16 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
EP2044063A1 (en) 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
KR20140103972A (ko) 2011-12-22 2014-08-27 에프. 호프만-라 로슈 아게 세린/트레오닌 키나아제 억제제로서의 2,4-다이아민-피리미딘 유도체
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (enExample) * 2014-08-21 2018-03-31
CN106687467A (zh) * 2014-09-30 2017-05-17 韩美精密化学株式会社 高纯度(r)‑9‑[2‑(磷酰甲氧基)丙基]腺嘌呤的制备方法
EP3303348B1 (en) * 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
US9938257B2 (en) 2015-09-11 2018-04-10 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
SMT202200409T1 (it) * 2017-10-27 2022-11-18 Theravance Biopharma R&D Ip Llc Composto di pirimidina come inibitore di chinasi jak
TW202106681A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ip有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
WO2020219639A1 (en) 2019-04-24 2020-10-29 Theravance Biopharma R&D Ip, Llc Ester and carbonate pyrimidine compounds as jak kinase inhibitors

Also Published As

Publication number Publication date
US20220396573A1 (en) 2022-12-15
SG11202001706RA (en) 2020-03-30
MD3672965T2 (ro) 2022-12-31
CU24671B1 (es) 2023-07-12
CA3074034A1 (en) 2019-05-02
DK3672965T3 (da) 2022-10-03
PL3672965T3 (pl) 2023-01-16
LT3672965T (lt) 2022-10-10
MA49956B1 (fr) 2022-11-30
CN111247142B (zh) 2022-12-02
CN111247142A (zh) 2020-06-05
US10774080B2 (en) 2020-09-15
AU2018354370B2 (en) 2023-04-27
DOP2020000083A (es) 2020-08-15
WO2019084383A1 (en) 2019-05-02
IL274037B1 (en) 2023-07-01
GEAP202115340A (en) 2021-08-10
ES2932526T3 (es) 2023-01-20
IL274037A (en) 2020-06-30
PE20201495A1 (es) 2020-12-29
US20190241555A1 (en) 2019-08-08
GEP20227344B (en) 2022-01-25
US20200369660A1 (en) 2020-11-26
PT3672965T (pt) 2022-09-29
KR102613503B1 (ko) 2023-12-13
PH12020500528A1 (en) 2021-06-07
EP3672965A1 (en) 2020-07-01
KR20200078517A (ko) 2020-07-01
CR20200180A (es) 2020-08-12
JP7218364B2 (ja) 2023-02-06
UA125130C2 (uk) 2022-01-12
AU2018354370A1 (en) 2020-04-09
ECSP20023795A (es) 2020-06-30
HUE060401T2 (hu) 2023-02-28
US10988470B2 (en) 2021-04-27
MX2020004255A (es) 2020-07-29
EA202091016A1 (ru) 2020-07-17
US20200140430A1 (en) 2020-05-07
TWI789446B (zh) 2023-01-11
SMT202200409T1 (it) 2022-11-18
US10308646B2 (en) 2019-06-04
US11814377B2 (en) 2023-11-14
US11420965B2 (en) 2022-08-23
BR112020008015A2 (pt) 2020-10-27
TW201930304A (zh) 2019-08-01
US20240158389A1 (en) 2024-05-16
NI202000032A (es) 2020-10-09
CU20200053A7 (es) 2021-03-11
ZA202001641B (en) 2021-04-28
US10562894B2 (en) 2020-02-18
US20210214349A1 (en) 2021-07-15
SI3672965T1 (sl) 2022-11-30
RS63608B1 (sr) 2022-10-31
US12172994B2 (en) 2024-12-24
EP3672965B1 (en) 2022-09-07
JP2021501151A (ja) 2021-01-14
MA49956A (fr) 2020-07-01
IL274037B2 (en) 2023-11-01
US20190127364A1 (en) 2019-05-02
CL2020001090A1 (es) 2020-08-21
HRP20221221T1 (hr) 2022-12-09

Similar Documents

Publication Publication Date Title
AR113803A1 (es) Compuesto de pirimidina como inhibidor de jak quinasas
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2019011809A2 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
MX2018015625A (es) Compuestos y composiciones para inhibir la actividad de shp2.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CL2017002650A1 (es) Compuestos novedosos
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CR20190156A (es) Derivados de bipirazol como inhibidores jak
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
EA201791576A1 (ru) Ингибитор jak
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
MX2020004283A (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CO2020000371A2 (es) Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos
CO2019008110A2 (es) Activador de nrf2
UA120927C2 (uk) Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana

Legal Events

Date Code Title Description
FB Suspension of granting procedure